A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus (AWARD-CHN1)
The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus
Sponsor: Eli Lilly and Company
Listed as NCT01644500, this PHASE3 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Eli Lilly and Company, it has been updated 10 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Nov 2018 — Oct 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changhua, Taiwan , Changsha, China , Chengdu, China , Chongqing, China , Gangwon-Do, South Korea , Guangzhou, China , Guiyang, China , Hangzhou, China , Harbin, China and 20 more locations